Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00128206 · ClinicalTrials.gov registry record · Phase 3
Treatment of Latent TB Infection for Jailed Persons
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 364
- Enrollment target
NCT00128206: Completed Phase 3 study, sponsored by University of California, San Francisco.
NCT00128206 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 364 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00128206, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 364 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an alternative drug, (rifampin) given daily, is better at treating tuberculosis (TB) and more tolerable than the usual drug treatment, isoniazid (INH). Study participants will include 972, TB infected, San Francisco Jail inmates, aged 18 or older. One group of volunteers will take INH two times a week for 9 months, and the other group will take rifampin daily for 4 months. Medication will be administered in jail and at the San Francisco TB Clinic if the volunteer is released from jail prior to completing the study. Participants will be seen daily for 4 months (rifampin group), and 2 times a week for 9 months (INH group) for directly observed therapy. Study procedures will include 5 symptom review visits and blood samples for lab testing. Follow-up will continue for each subject for five years after enrollment into the study.
Primary Outcome
Liver function tests were taken at regular intervals and clinical symptoms were reviewed at regular intervals in both study groups. On the basis of these tests and examinations, physicians determined whether the study drug needed to be stopped.
Interventions
- DRUG Rifampin
- DRUG Isoniazid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
What the finished NCT00128206 record still lists
NCT00128206 is an interventional study that assigns participants to a tested intervention. The registered 364 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT00128206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00128206 about?
NCT00128206 is a clinical study titled "Treatment of Latent TB Infection for Jailed Persons". The purpose of this study is to determine whether an alternative drug, (rifampin) given daily, is better at treating tuberculosis (TB) and more tolerable than the usual drug treatment, isoniazid (INH). Study participants will include 972, TB infected, San Francisco Jail inmates, aged 18 or older. On...
What is the current status of trial NCT00128206?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 364 participants. The study started on 2004-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00128206?
The interventions under investigation include: Rifampin (DRUG), Isoniazid (DRUG).
Who is sponsoring clinical trial NCT00128206?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00128206's enrollment target sits among peer trials
364 1003rd of 2000 higher than 996 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05330221 · 364 participants · NA
Project 2: ACHIEVE- HF
- NCT05673148 · 364 participants · Phase 3
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia